Chronic respiratory diseases such as COPD are highly heterogeneous and the traditional “one size fits all” treatment approach has largely failed. However, by stratifying patients based on subtypes using biomarkers, there is a potential to enhance the success rate in clinical trials by recruiting patients with the greatest likelihood of treatment response.

Progressive pulmonary fibrosis is associated with an abnormal lung tissue remodeling and excessive extracellular matrix deposition. The Nordic ProteinFingerPrint Technology^TM can measure these processes with tailored biomarkers of lung tissue remodeling, epithelial damage, wound healing, and inflammation. Read more about how our biomarkers for pulmonary fibrosis can be used prognostically, pharmacodynamically, and translationally to support drug development.